Inhibition of BRAF and MEK in BRAF-mutant melanoma

The Lancet

Volumn 386, Issue 9992, 2015, Pages 410-412

  Smalley, Keiran S M ^a   Sondak, Vernon K ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; CYCLIN D1; CYCLIN DEPENDENT KINASE 4; DABRAFENIB; HEAT SHOCK PROTEIN 90; LACTATE DEHYDROGENASE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; TRAMETINIB; IMIDAZOLES; OXIMES; PYRIDONES; PYRIMIDINONES;

BRAF MUTANT MELANOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; DRUG EFFICACY; DRUG TREATMENT FAILURE; ENZYME INHIBITION; ENZYME REACTIVATION; FOLLOW UP; GENE MUTATION; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; MELANOMA; MONOTHERAPY; NONHUMAN; NOTE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIGNAL TRANSDUCTION; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; FEMALE; HUMANS; MALE;

FEMALE; HUMANS; IMIDAZOLES; MALE; MELANOMA; OXIMES; PYRIDONES; PYRIMIDINONES;

EID: 84938742411     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(15)60972-2     Document Type: Note

References (12)

1. GV Long, D Stroyakovskiy, H Gogas et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial Lancet 2015 published online May 31. http://dx.doi.org/10.1016/S0140-6736(15)60898-4
2. IV Fedorenko, GT Gibney, VK Sondak, KS Smalley Beyond BRAF: where next for melanoma therapy? Br J Cancer 112 2015 217 226
3. KT Flaherty, JR Infante, A Daud et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations N Engl J Med 367 2012 1694 1703
4. J Larkin, PA Ascierto, B Dreno et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma N Engl J Med 371 2014 1867 1876
5. C Robert, B Karaszewska, J Schachter et al. Improved overall survival in melanoma with combined dabrafenib and trametinib N Engl J Med 372 2015 30 39
6. GV Long, D Stroyakovskiy, H Gogas et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma N Engl J Med 371 2014 1877 1888
7. N Wagle, EM Van Allen, DJ Treacy et al. MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition Cancer Discov 4 2014 61 68
8. DB Johnson, KT Flaherty, JS Weber et al. Combined BRAF (dabrafenib) and MEK inhibition (trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor J Clin Oncol 32 2014 3697 3704
9. V Yadav, TF Burke, L Huber et al. The CDK4/6 inhibitor LY2835219 overcomes vemurafenib resistance resulting from MAPK reactivation and cyclin D1 upregulation Mol Cancer Ther 13 2014 2253 2263
10. T Smyth, KH Paraiso, K Hearn et al. Inhibition of HSP90 by AT13387 delays the emergence of resistance to BRAF inhibitors and overcomes resistance to dual BRAF and MEK inhibition in melanoma models Mol Cancer Ther 13 2014 2793 2804
11. C Robert, GV Long, B Brady et al. Nivolumab in previously untreated melanoma without BRAF mutation N Engl J Med 372 2015 320 330
12. MA Postow, J Chesney, AC Pavlick et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma N Engl J Med 372 2015 2006 2017